Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emcure Pharmaceuticals reported consolidated revenue of Rs. 2,101 crore for Q1FY26, up 15.7% year-on-year, driven by 9.4% growth in the domestic business (Rs. 995 crore) and 22.1% growth in the international business (Rs. 1,106 crore). EBITDA rose 20.1% to Rs. 404 crore with margins expanding to 19.2% from 18.5% a year ago. Profit after tax jumped about 41% to Rs. 215 crore. The company booked a Rs. 35 crore exceptional expense for a one-time legal settlement. Key subsidiaries Tillomed acquired Manx Healthcare's product portfolio for around Rs. 2,202 crore, and the board approved buying out minority shareholders in Zuventus Healthcare to make it wholly owned. Statutory auditors B S R & Co. LLP issued an unqualified limited review report on the results.
Strong Q1 with double-digit revenue growth, margin expansion, and over 40% PAT growth signals healthy operational momentum, likely to be viewed positively by investors. The Zuventus buyout and expanded Sanofi partnership are incremental positives for the franchise.